Scientists is engaging on a malaria vaccine have informed that the vaccine has passed a critical breakthrough in human life safety trials. The solution employed a natively modified form of the virus which was impotent to cause a full infection in people. The results of this study were published, Jan. 4, in the journal Science Translational Medicine, and have been categorized as "promising" by tropical disease specialists.

One Step Closer To Malaria Vaccine

As part of the human test, none of the 10 volunteered subjects developed the disease, and the treatment directed to them had no severe side-effects. The virus endures various stages in people as well as mosquitoes. Starting from this foundation, the team of scientists removed three genes, which made the liver infection intolerable to complete.

The results of this research are all the more hopeful, as there are roughly 5,000 malaria genes, and through the erasure of three of them, formidable results were attained. The technique behind this strategy is that individuals are infected with the weakened virus, exposing their immune system. Since the lifespan of the parasite cannot be finalized, the disease will not install in the human body.

Further, the antibodies of the patients were managed to mice, which responded to the reflected infection with a higher overall struggle. "The medical study now shows that the serum is totally weakened in humans and also shows that even after only a single management, it elicits a robust immune reaction against the malaria pest," noted Dr Sebastian Mikolajczak, researcher of the study.

So far, two main orders have been developed in response to the hazard of this virus. The first one consists of wearying the virus itself by exposing it to radiation, while the second one, applied as part of the current research, involves consolidation the patient. The latter is a mixture of administering the anti-malarial drugs to the patients and contaminating them with the weakened virus at the same time, which generates a positive response from the immune system.

"Immunization of humans with whole sporozoites gives complete, sterilizing resistance against malaria infection. However, achieving dependable safety while maintaining immunogenicity of whole parasite vaccines remains a difficult challenge," indications of the study.

Malaria, An Ongoing Threat

A completely practicable vaccine is, however, far from being settled. While there are a high number of trials under tests, the virus still affects approximately 200 million people by the year, as research points out. The disease seems because of plasmodium, a microscopic parasite that blights the human body through the means of mosquito bites, which allow a form of the parasite to get under the human skin.

Once inside the human body, the virus occurrences the liver, where its sporozoites infected the organ with 30,000 copies of the pest. From the liver, the virus gets into the blood stream, where it attacks red blood cells, which from time to time results into the patient's death.

Because the contamination follows these three stages, it is more difficult to create a fully functional vaccine to prevent it from spreading all over the body and, finally, affecting the blood cells.